XL‑protein Launches Spin-Off PASylANTA Therapeutics to Develop Long‑Acting IL‑1Ra Biobetters

In this episode of Global Economic Press, Alex Brady delves into the biotechnology sector with a spotlight on PASylANTA Therapeutics, a new spin-off from XL-protein GmbH. This Germany-based company is poised to transform long-term disease management through its innovative development of long-acting interleukin-1 receptor antagonist therapies. By leveraging XL-protein's proprietary PASylation technology, PASylANTA aims to extend the half-life of biologics without synthetic polymers, offering a next-generation approach to engineering long-acting protein or peptide therapeutics with enhanced pharmacokinetics and safety profiles. PASylANTA's lead program focuses on applying PASylation technology to the interleukin-1 receptor antagonist, an approved drug currently administered daily, to create a therapeutic candidate that allows for weekly dosing. This advancement could significantly improve treatment adherence. The company is led by a seasoned team, including Sergio Lai as Chief Executive Officer, and is supported by key opinion leaders in rheumatology, immunology, and autoinflammatory diseases. As PASylANTA advances its development strategy, it aims to engage with the broader biotechnology, clinical, and investor communities. For more information about XL-protein GmbH and its innovative technologies, visit their website at https://xl-protein.com.